Revisiting Experimental Models of Diabetic Nephropathy.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
19 May 2020
Historique:
received: 14 04 2020
revised: 12 05 2020
accepted: 13 05 2020
entrez: 23 5 2020
pubmed: 23 5 2020
medline: 11 2 2021
Statut: epublish

Résumé

Diabetes prevalence is constantly increasing and, nowadays, it affects more than 350 million people worldwide. Therefore, the prevalence of diabetic nephropathy (DN) has also increased, becoming the main cause of end-stage renal disease (ESRD) in the developed world. DN is characterized by albuminuria, a decline in glomerular filtration rate (GFR), hypertension, mesangial matrix expansion, glomerular basement membrane thickening, and tubulointerstitial fibrosis. The therapeutic advances in the last years have been able to modify and delay the natural course of diabetic kidney disease (DKD). Nevertheless, there is still an urgent need to characterize the pathways that are involved in DN, identify risk biomarkers and prevent kidney failure in diabetic patients. Rodent models provide valuable information regarding how DN is set and its progression through time. Despite the utility of these models, kidney disease progression depends on the diabetes induction method and susceptibility to diabetes of each experimental strain. The classical DN murine models (Streptozotocin-induced, Akita, or obese type 2 models) do not develop all of the typical DN features. For this reason, many models have been crossed to a susceptible genetic background. Knockout and transgenic strains have also been created to generate more robust models. In this review, we will focus on the description of the new DN rodent models and, additionally, we will provide an overview of the available methods for renal phenotyping.

Identifiants

pubmed: 32438732
pii: ijms21103587
doi: 10.3390/ijms21103587
pmc: PMC7278948
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Instituto de Salud Carlos III
ID : PI17/00257
Organisme : Instituto de Salud Carlos III
ID : PI18/01704
Organisme : Instituto de Salud Carlos III
ID : RD16/0009/0030

Références

N Engl J Med. 1987 Nov 26;317(22):1390-8
pubmed: 3317040
N Engl J Med. 2006 Jun 8;354(23):2473-83
pubmed: 16760447
Kidney Int. 1999 Jul;56(1):118-34
pubmed: 10411685
Lancet. 1995 Oct 21;346(8982):1080-4
pubmed: 7564792
J Diabetes Res. 2016;2016:2902351
pubmed: 27547764
Nephron Exp Nephrol. 2014;126(4):191-5
pubmed: 25034792
J Biol Chem. 1994 Dec 23;269(51):32634-8
pubmed: 7798269
Hypertens Res. 2010 Aug;33(8):772-7
pubmed: 20505673
Clin Kidney J. 2019 Mar 06;12(3):322-325
pubmed: 31198226
Am J Pathol. 2007 Nov;171(5):1441-50
pubmed: 17884968
Nephron. 1991;58(2):210-8
pubmed: 1865980
J Am Soc Nephrol. 2012 Mar;23(3):405-11
pubmed: 22193383
Clin Epigenetics. 2013 Nov 19;5(1):21
pubmed: 24246027
J Am Soc Nephrol. 2006 Nov;17(11):3067-75
pubmed: 17021266
Diabetes. 2005 Sep;54(9):2628-37
pubmed: 16123351
Nat Commun. 2017 Sep 4;8(1):413
pubmed: 28871079
Am J Physiol Renal Physiol. 2010 Jul;299(1):F99-F111
pubmed: 20375117
Curr Diab Rep. 2015 Jul;15(7):41
pubmed: 25971618
Physiol Rep. 2017 Mar;5(5):
pubmed: 28292877
Kidney Int. 2010 Jan;77(1):57-64
pubmed: 19847154
Am J Physiol Renal Physiol. 2010 Mar;298(3):F788-95
pubmed: 20042456
Diabetologia. 2012 Sep;55(9):2301-6
pubmed: 22696035
Curr Protoc Pharmacol. 2015 Sep 01;70:5.47.1-5.47.20
pubmed: 26331889
Am J Physiol Renal Physiol. 2011 Mar;300(3):F618-25
pubmed: 21147841
Am J Physiol Renal Physiol. 2003 Jun;284(6):F1138-44
pubmed: 12736165
Am J Physiol Renal Physiol. 2012 Sep;303(5):F783-8
pubmed: 22696603
Nat Rev Nephrol. 2016 Feb;12(2):73-81
pubmed: 26553517
Proc Natl Acad Sci U S A. 2004 Sep 7;101(36):13302-5
pubmed: 15326315
Vet Pathol. 2016 Mar;53(2):468-76
pubmed: 26604215
Diabetes Metab Res Rev. 2004 Nov-Dec;20(6):452-9
pubmed: 15386825
PLoS One. 2016 Aug 31;11(8):e0162131
pubmed: 27579698
Diabetes. 2004 Feb;53 Suppl 1:S4-11
pubmed: 14749259
Am J Ther. 2005 Nov-Dec;12(6):491-8
pubmed: 16280642
PLoS One. 2016 Apr 20;11(4):e0153965
pubmed: 27097221
J Submicrosc Cytol Pathol. 2001 Oct;33(4):443-51
pubmed: 11989778
Kidney Int. 2007 Sep;72(5):614-23
pubmed: 17579661
PLoS One. 2014 Dec 16;9(12):e113459
pubmed: 25514595
J Vasc Res. 2004 Nov-Dec;41(6):499-508
pubmed: 15528932
Adv Chronic Kidney Dis. 2011 Jul;18(4):243-8
pubmed: 21782130
Kidney Int. 2013 Aug;84(2):265-76
pubmed: 23594678
J Clin Invest. 1995 May;95(5):2338-45
pubmed: 7738197
PLoS One. 2014 Jan 06;9(1):e84683
pubmed: 24400109
Am J Physiol Renal Physiol. 2018 Dec 1;315(6):F1644-F1651
pubmed: 30256126
Proc Natl Acad Sci U S A. 2000 Jul 5;97(14):8015-20
pubmed: 10859350
Adv Chronic Kidney Dis. 2014 May;21(3):267-72
pubmed: 24780454
PLoS One. 2012;7(3):e32746
pubmed: 22412919
J Hypertens. 2003 Sep;21(9):1729-36
pubmed: 12923406
N Engl J Med. 2019 Jun 13;380(24):2295-2306
pubmed: 30990260
Am J Physiol Renal Physiol. 2009 Apr;296(4):F819-29
pubmed: 19211686
Proc Natl Acad Sci U S A. 2010 Jun 1;107(22):10190-5
pubmed: 20479236
J Am Soc Nephrol. 2006 Oct;17(10):2664-9
pubmed: 16971655
Exp Diabetes Res. 2012;2012:616313
pubmed: 22461787
Lab Anim. 2012 Jan;46(1):32-9
pubmed: 22087029
J Hypertens. 2016 Sep;34(9):1752-65
pubmed: 27379538
Am J Pathol. 2007 May;170(5):1473-84
pubmed: 17456755
Diabetologia. 2004 Sep;47(9):1541-9
pubmed: 15338127
J Diabetes Res. 2017;2017:8503754
pubmed: 29038790
Am J Physiol Renal Physiol. 2017 Jan 1;312(1):F210-F229
pubmed: 27707704
Curr Diab Rep. 2016 Feb;16(2):18
pubmed: 26814757
Int Urol Nephrol. 2019 Apr;51(4):755-764
pubmed: 30734886
J Am Soc Nephrol. 2009 Dec;20(12):2503-12
pubmed: 19729434
Kidney Int. 1982 May;21(5):689-95
pubmed: 6981023
Kidney Blood Press Res. 2017;42(6):1128-1140
pubmed: 29224015
Cell Tissue Res. 2015 Nov;362(2):307-15
pubmed: 26033221
Diabetologia. 1996 Aug;39(8):940-5
pubmed: 8858216
JAMA. 2016 Aug 9;316(6):602-10
pubmed: 27532915
Nephron. 2016;133(1):62-70
pubmed: 27160992
J Biol Chem. 2005 Apr 22;280(16):15767-72
pubmed: 15701628
PLoS One. 2015 Apr 13;10(4):e0123753
pubmed: 25875005
Biomed Pharmacother. 2018 Jul;103:59-66
pubmed: 29635129
Am J Physiol Renal Physiol. 2006 Jan;290(1):F214-22
pubmed: 16118394
J Am Soc Nephrol. 2014 May;25(5):1118-29
pubmed: 24357669
Kidney Int. 2005 Dec;68(6):2562-71
pubmed: 16316331
Am J Physiol. 1991 Feb;260(2 Pt 2):F185-91
pubmed: 1996670
Arch Pathol Lab Med. 2006 May;130(5):699-706
pubmed: 16683888
J Vis Exp. 2018 Jun 30;(136):
pubmed: 30010634
Kidney Int. 1997 May;51(5):1624-8
pubmed: 9150483
J Am Soc Nephrol. 2010 Apr;21(4):556-63
pubmed: 20167701
Lab Invest. 2018 Sep;98(9):1237-1249
pubmed: 29884907
J Clin Med. 2019 Jun 17;8(6):
pubmed: 31212945
Lancet. 2013 Jul 20;382(9888):260-72
pubmed: 23727169
J Am Soc Nephrol. 2003 Oct;14(10):2484-93
pubmed: 14514726
Curr Opin Nephrol Hypertens. 2011 May;20(3):278-84
pubmed: 21422926
Hypertension. 1999 Oct;34(4 Pt 1):563-7
pubmed: 10523327
Nephrology (Carlton). 2014 Dec;19(12):802-13
pubmed: 25196678
J Am Soc Nephrol. 2007 Feb;18(2):539-50
pubmed: 17202420
J Microsc. 1979 Jan;115(1):19-33
pubmed: 423237
Am J Pathol. 2001 May;158(5):1653-63
pubmed: 11337363
Neurosci Lett. 2017 Feb 15;640:60-63
pubmed: 28093305
Nephrology (Carlton). 2007 Dec;12(6):553-8
pubmed: 17995580
JAMA. 2014 Jun 25;311(24):2518-2531
pubmed: 24892770
J Am Soc Nephrol. 2010 Sep;21(9):1533-42
pubmed: 20634301
Lab Anim. 2011 Jul;45(3):131-40
pubmed: 21478271
Lab Invest. 2002 Jul;82(7):833-42
pubmed: 12118085
J Diabetes Res. 2016;2016:9051426
pubmed: 27595114
Diabetes. 2016 Jan;65(1):25-33
pubmed: 26696638
Nat Rev Nephrol. 2018 Jan;14(1):48-56
pubmed: 29062142

Auteurs

Anna Giralt-López (A)

Nephrology Research Group, Vall d'Hebrón Institut de Recerca, 08035 Barcelona, Spain.

Mireia Molina-Van den Bosch (M)

Nephrology Research Group, Vall d'Hebrón Institut de Recerca, 08035 Barcelona, Spain.

Ander Vergara (A)

Nephrology Research Group, Vall d'Hebrón Institut de Recerca, 08035 Barcelona, Spain.
Nephrology Department, Vall d'Hebrón Hospital, 08035 Barcelona, Spain.

Clara García-Carro (C)

Nephrology Research Group, Vall d'Hebrón Institut de Recerca, 08035 Barcelona, Spain.
Nephrology Department, Vall d'Hebrón Hospital, 08035 Barcelona, Spain.

Daniel Seron (D)

Nephrology Research Group, Vall d'Hebrón Institut de Recerca, 08035 Barcelona, Spain.
Nephrology Department, Vall d'Hebrón Hospital, 08035 Barcelona, Spain.

Conxita Jacobs-Cachá (C)

Nephrology Research Group, Vall d'Hebrón Institut de Recerca, 08035 Barcelona, Spain.

Maria José Soler (MJ)

Nephrology Research Group, Vall d'Hebrón Institut de Recerca, 08035 Barcelona, Spain.
Nephrology Department, Vall d'Hebrón Hospital, 08035 Barcelona, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH